Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2016

View Archived Issues

Normalizing standard laboratory mouse husbandry replicates adult human immune traits

RSPO3 is a potential biomarker of cholangitis

Brigatinib granted U.S. orphan designation for ALK-, ROS1- or EGFR-positive NSCLC

Gilead's MAA for Odefsey single tablet regimen receives positive opinion for the treatment of HIV

Merck & Co. patents PAR1 receptor antagonists

Daclizumab recommended for approval in E.U.

Interim results reported from CyTuVax's phase I study of hepatitis B vaccine

Avibactam/ceftazidime gets positive opinion from CHMP

MEG3 levels are increased in hypoxia-induced pulmonary hypertension

Antitumor activity observed in RAS-mutant cancers in phase I study of BGB-283

Cempra completes rolling NDA submissions for solithromycin in CABP

Corcept advances selective cortisol modulator CORT-125134 in clinic

AB Science submits MAA in E.U. for masitinib to treat severe systemic mastocytosis

AbbVie updates pipeline progress of first quarter 2016

EPI-743 improves CNS markers of oxidative stress and retinal function in PD

miR-873's effects on glycine N-methyltransferase can be targeted to reduce liver injury

FDA approves Nuplazid for hallucinations and delusions associated with Parkinson's disease psychosis

CHMP backs approval of Imbruvica in CLL

Marathon Pharmaceuticals discloses phase III results of deflazacort and prednisone for DMD

Oncurious announces new phase I/IIa study of TB-403 for medulloblastoma

Medivation rejects Sanofi's offer

EMA committee backs marketing authorization for Enzepi

FDA grants emergency use authorization to Quest Diagnostics' Zika virus test

BAY-1436032 shows promising antitumor activity in vivo

Bristol-Myers Squibb offers overview of first quarter 2016